AR060732A1 - USES OF ESCITALOPRAM - Google Patents
USES OF ESCITALOPRAMInfo
- Publication number
- AR060732A1 AR060732A1 ARP070101874A ARP070101874A AR060732A1 AR 060732 A1 AR060732 A1 AR 060732A1 AR P070101874 A ARP070101874 A AR P070101874A AR P070101874 A ARP070101874 A AR P070101874A AR 060732 A1 AR060732 A1 AR 060732A1
- Authority
- AR
- Argentina
- Prior art keywords
- escitalopram
- isobenzofurancarbonitrile
- fluorphenyl
- inn
- diminished
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente se relaciona con el uso del compuesto escitalopram (nombre de INN), es decir, (S)-1-[3-(di-metil-amino)propil]-1-(4-fluorfenil)-1,3- dihidro-5-isobenzofurancarbonitrilo, o una sal farmacéuticamente aceptable del mismo, para la preparacion de un medicamento para mejorar la cognicion en un trastorno en que los procesos cognitivos están disminuidos.This is related to the use of the compound escitalopram (name of INN), that is, (S) -1- [3- (di-methyl-amino) propyl] -1- (4-fluorphenyl) -1,3- dihydro-5-isobenzofurancarbonitrile, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for improving cognition in a disorder in which cognitive processes are diminished.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200600621 | 2006-05-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR060732A1 true AR060732A1 (en) | 2008-07-10 |
Family
ID=38134951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070101874A AR060732A1 (en) | 2006-05-02 | 2007-04-30 | USES OF ESCITALOPRAM |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP2026793A2 (en) |
JP (1) | JP2009535367A (en) |
KR (1) | KR20090009820A (en) |
CN (1) | CN101426494A (en) |
AR (1) | AR060732A1 (en) |
AU (1) | AU2007245983A1 (en) |
BR (1) | BRPI0710230A2 (en) |
CA (1) | CA2651002A1 (en) |
EA (1) | EA200870491A1 (en) |
IL (1) | IL194628A0 (en) |
MX (1) | MX2008013911A (en) |
NO (1) | NO20085009L (en) |
TW (1) | TW200812993A (en) |
WO (1) | WO2007124757A2 (en) |
ZA (1) | ZA200808632B (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE431147T1 (en) | 2002-08-22 | 2009-05-15 | Dainippon Sumitomo Pharma Co | AGENTS FOR TREATING INTEGRATION DYSFUNCTION SYNDROME |
WO2004113333A1 (en) | 2003-06-23 | 2004-12-29 | Dainippon Sumitomo Pharma Co., Ltd. | Therapeutic agent for senile dementia |
US20070160537A1 (en) | 2004-02-20 | 2007-07-12 | Takeo Ishiyama | In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia |
US20090036468A1 (en) * | 2007-08-03 | 2009-02-05 | Forest Laboratories Holdings Limited | Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands |
EP2236138A1 (en) * | 2009-03-30 | 2010-10-06 | PharmaNeuroBoost N.V. | Low dose pipamperone in treating mood and anxiety disorders |
US8258139B2 (en) * | 2010-11-08 | 2012-09-04 | Dainippon Sumitomo Pharma Co., Ltd. | Method of treatment for mental disorders |
EP3069718A1 (en) | 2015-03-17 | 2016-09-21 | Universidade do Minho | Citalopram or escitalopram for use in the treatment of neurodegenerative diseases |
RU2764443C2 (en) | 2016-12-20 | 2022-01-17 | Лтс Ломанн Терапи-Систем Аг | Transdermal therapeutic system containing azenapine and polysiloxane or polyisobutylene |
RU2762896C2 (en) | 2016-12-20 | 2021-12-23 | Лтс Ломанн Терапи-Систем Аг | Transdermal therapeutic system containing asenapine |
WO2019002204A1 (en) | 2017-06-26 | 2019-01-03 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer |
CN112704672A (en) | 2018-06-20 | 2021-04-27 | 罗曼治疗***股份公司 | Transdermal therapeutic system comprising asenapine |
KR102051624B1 (en) * | 2018-11-30 | 2019-12-02 | 아밀로이드솔루션 주식회사 | Pharmaceutical composition for treatment of neurodegenerative brain disease comprising triflupromazine or pharmacurically acceptable salt thereof as an active ingredient |
CN109464436A (en) * | 2019-01-10 | 2019-03-15 | 高智玉 | Citalopram or escitalopram combine the application in the compound preparation of preparation treatment phrenoblabia class disease with Quetiapine respectively |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK213290D0 (en) * | 1990-09-06 | 1990-09-06 | Lundbeck & Co As H | TREATMENT OF CEREBROVASCULAR DISORDERS |
SE9803157D0 (en) * | 1998-09-16 | 1998-09-16 | Astra Ab | A new composition |
SE9803158D0 (en) * | 1998-09-16 | 1998-09-16 | Astra Ab | A new composition |
US6617361B2 (en) * | 1999-11-05 | 2003-09-09 | Be Able, Llc | Behavior chemotherapy |
CN100457182C (en) * | 2000-12-01 | 2009-02-04 | 可以有限公司 | Behavior chemotherapy |
WO2002076461A1 (en) * | 2001-03-26 | 2002-10-03 | Serdar Murat Dursun | Combination of reboxetine and citalopram |
EA200301195A1 (en) * | 2001-05-01 | 2004-04-29 | Х. Лундбекк А/С | APPLICATION OF ENANTIOMERALLY CLEAN ESCYTAL PREMA |
US20050014848A1 (en) * | 2002-01-23 | 2005-01-20 | Pfizer Inc. | Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors |
AU2003268026A1 (en) * | 2002-07-30 | 2004-02-16 | Peter Migaly | Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions |
CA2511142A1 (en) * | 2002-12-23 | 2004-07-08 | H. Lundbeck A/S | Escitalopram hydrobromide and a method for the preparation thereof |
MXPA06002504A (en) * | 2003-09-04 | 2006-06-20 | Lundbeck & Co As H | The combination of a serotonin reuptake inhibitor and loxapine. |
JP2009511606A (en) * | 2005-10-14 | 2009-03-19 | ハー・ルンドベック・アクチエゼルスカベット | Methods of treating central nervous system disorders using a low-dose combination of escitalopram and bupropion |
EA200801080A1 (en) * | 2005-10-14 | 2009-02-27 | Х. Лундбекк А/С | STABLE PHARMACEUTICAL MEDICINE FORMS CONTAINING ESCITALOPRAM AND BUPROPION |
US20070134322A1 (en) * | 2005-12-14 | 2007-06-14 | Forest Laboratories, Inc. | Modified and pulsatile release pharmaceutical formulations of escitalopram |
-
2007
- 2007-04-25 TW TW096114520A patent/TW200812993A/en unknown
- 2007-04-30 AR ARP070101874A patent/AR060732A1/en unknown
- 2007-04-30 CA CA002651002A patent/CA2651002A1/en not_active Abandoned
- 2007-04-30 EP EP07722705A patent/EP2026793A2/en not_active Withdrawn
- 2007-04-30 JP JP2009508134A patent/JP2009535367A/en not_active Withdrawn
- 2007-04-30 EA EA200870491A patent/EA200870491A1/en unknown
- 2007-04-30 MX MX2008013911A patent/MX2008013911A/en not_active Application Discontinuation
- 2007-04-30 KR KR1020087025797A patent/KR20090009820A/en not_active Application Discontinuation
- 2007-04-30 BR BRPI0710230-5A patent/BRPI0710230A2/en not_active IP Right Cessation
- 2007-04-30 AU AU2007245983A patent/AU2007245983A1/en not_active Abandoned
- 2007-04-30 WO PCT/DK2007/050050 patent/WO2007124757A2/en active Application Filing
- 2007-04-30 CN CNA200780014675XA patent/CN101426494A/en active Pending
-
2008
- 2008-10-07 IL IL194628A patent/IL194628A0/en unknown
- 2008-10-09 ZA ZA2008/08632A patent/ZA200808632B/en unknown
- 2008-12-02 NO NO20085009A patent/NO20085009L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN101426494A (en) | 2009-05-06 |
JP2009535367A (en) | 2009-10-01 |
CA2651002A1 (en) | 2007-11-08 |
EA200870491A1 (en) | 2009-04-28 |
BRPI0710230A2 (en) | 2011-08-02 |
NO20085009L (en) | 2008-12-16 |
KR20090009820A (en) | 2009-01-23 |
ZA200808632B (en) | 2009-12-30 |
WO2007124757A2 (en) | 2007-11-08 |
WO2007124757A3 (en) | 2008-07-24 |
EP2026793A2 (en) | 2009-02-25 |
TW200812993A (en) | 2008-03-16 |
AU2007245983A1 (en) | 2007-11-08 |
IL194628A0 (en) | 2009-08-03 |
MX2008013911A (en) | 2008-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR060732A1 (en) | USES OF ESCITALOPRAM | |
CL2008003822A1 (en) | Compounds derived from n1- (2-thiazolyl) -1,2-dicarboxamide pyrrolidine; preparation procedure; pharmaceutical composition; pharmaceutical combination; and use for the treatment of diseases ameliorated by phosphatidylinositol-3-kinase inhibition, such as cancer. | |
CL2007002197A1 (en) | COMPOUNDS DERIVED FROM INDOL; PREPARATION PROCEDURE; INTERMEDIARY COMPOUND; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF MELLITUS DIABETES, DIABETIC RETINOPATHY, HYPERGLUCEMIA, HYPERL | |
NO20091260L (en) | Combination therapy for diabetes mellitus | |
CL2008002228A1 (en) | Compounds derived from imidazopyridinones, tlr7 agonist; preparation procedure; intermediate compounds; pharmaceutical composition comprising them; and use in viral, bacterial and fungal infections. | |
UY31554A1 (en) | NEW INHIBITORS OF ACETIL COENZIMA TO CARBOXYLASE AND USES IN OBESITY TREATMENTS AND MELLITUS DIABETES | |
CL2007003686A1 (en) | COMPOUNDS DERIVED FROM INDOL WITH UNITED RING IN POSITIONS 4,5; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND TO TREAT A VIRAL INFECTION. | |
ECSP12011799A (en) | ESPIROPIPERIDINE AND PHARMACEUTICAL USE OF THE SAME COMPOUNDS | |
PE20142371A1 (en) | PHARMACEUTICAL COMBINATION OF 3- (3-DIMETHYLAMINE-1-ETHYL-2-METHYL-PROPYL) -PHENOL AND AN ANTIEPYLEPTIC | |
CL2011000835A1 (en) | Compounds derived from spiro-oxindole; sodium channel modulators; pharmaceutical composition comprising said compound; and use in the treatment of pain, depression, cardiovascular, respiratory, psychiatric diseases, among others. | |
PA8785401A1 (en) | BENCIMIDAZOL DERIVATIVES | |
CL2012000033A1 (en) | Compounds n- (3- (4as, 7as) -2-amino-4a, 5,7,7a-tetrahydro-4h-furo [3,4-d] [1,3] thiazin-7a-yl) -4- fluorophenyl) -5-fluoropiconylamide, bace inhibitor; pharmaceutical composition comprising them, use of the compound for the treatment of Alzheimer's disease. | |
CL2012002944A1 (en) | Compounds derived from amino-pyrimidines; pharmaceutical compositions comprising them; and its use for the treatment of a disease selected condition of neuromuscular disorders, amyotrophic lateral sclerosis, myasthenia gravis, among others. | |
CL2012002945A1 (en) | Compounds derived from amino-pyridazines; pharmaceutical compositions comprising them; and its use for the treatment of a disease selected condition of neuromuscular disorders, amyotrophic lateral sclerosis, myasthenia gravis, among others. | |
CL2007002971A1 (en) | COMPOUNDS DERIVED FROM AMINOMETIL-4-IMIDAZOL; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM; AND ITS USE TO TREAT DEPRESSION, ANXIETY, BIPOLAR DISORDER, AMONG OTHERS. | |
CL2011002706A1 (en) | Compounds derived from 4- (1,3-oxazol-2-yl) -1h-indazole; pharmaceutical composition that includes them; and its uses in the treatment of diseases such as epoc, autoimmune, asthma, among others. | |
CL2009000349A1 (en) | Compounds derived from 4,5-dihydro-oxazol-2-ylamine; preparation procedure; pharmaceutical composition; and its use for the treatment of Alzheimer's disease. | |
CL2007003803A1 (en) | COMPOUNDS DERIVED FROM SULFONAMIDS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER, DYSLIPIDEMIA, DIABETES, OBESITY, INFECTION. | |
EA201692167A1 (en) | MODULATORS OF TOLL-SECONDARY RECEPTORS | |
CL2008001049A1 (en) | COMPOUNDS DERIVED FROM SUBSTITUTED BENZAMIDS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF DIABETES, INTOLERANCE TO GLUCOSE, DISLIPIDEMIA, HYPERTENSION, OBESITY. | |
AR068369A1 (en) | N4 XINAFOATE SALT - [(2,2-DIFLUOR-4H-BENZO [1,4] OXAZIN-3-ON) -6-IL] -5-FLUOR-N2- [3- (METHYLAMINOCARBONYLMETHYLENE) -FENYL] 2 , 4-PYRIMIDINDIAMINE " | |
CL2011000544A1 (en) | Compounds derived from benzamide n substituted by heterocycle, cannabinoid receptor ligands; pharmaceutical composition; and its use to treat pain, among other diseases. | |
CL2011002206A1 (en) | Compounds derived from substituted benzofuran, modulators of the igf1 signaling agent or activator of protein kinase b; pharmaceutical composition that includes them; Useful in the treatment of diseases of the CNS, such as Alzheimer's, among others. | |
CL2008002049A1 (en) | Macrocyclic aminoindole derived compounds; pharmaceutical composition comprising said compound; and use of the compound for the treatment of hepatitis c. | |
CL2007002970A1 (en) | COMPOUNDS DERIVED FROM AMINOMETIL-4-IMIDAZOL; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM; AND ITS USE TO TREAT DEPRESSION, ANXIETY, BIPOLAR DISORDER, AMONG OTHERS. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |